Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of ABP 501 and Adalimumab in Healthy Japanese Subjects
NCT05995691Phase 1Completed
- Sponsor
- Amgen
- Start
- Nov 2014
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, single-blind trial of adalimumab in rheumatoid arthritis (RA) and psoriasis (2 arms), sponsored by Amgen. Primary endpoints: Area Under the Serum Concentration-time Curve from Time 0 Extrapolated to Infinity and Maximum Observed Serum Concentration. Started Nov 2014; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriasis
Beyond the preview
Go deeper on NCT05995691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995691.